Single Center Registration Study on HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer
NCT ID: NCT06146114
Last Updated: 2023-11-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100 participants
OBSERVATIONAL
2023-07-01
2024-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. (1) Main Purpose
Analyze the expression of HER2 in prostate cancer patients admitted to Qilu Hospital of Shandong University.
(2) Secondary purpose
The expression of HER2 protein under different clinical and pathological characteristics (age, TNM grade, primary, and metastasis).
3.Main indicators:
The expression of HER2 in prostate cancer patients.
Secondary indicators:
1. The correlation between HER2 expression (IHC0/1+/2+/3+) and disease characteristics in locally advanced or metastatic prostate cancer patients;
2. The distribution of HER2 expression in different ages, different parts, different degrees of differentiation, and different TNM stages; Evaluate the expression of primary and metastatic lesions in patients with metastasis
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
experimental group
1. Prostate cancer patients confirmed by histopathology in our hospital from January 2018 to July 2023;
2. Men aged ≥ 18 years old;
3. The expected survival time is greater than 12 weeks;
4. The KPS functional status score is greater than 60, and the ECOG status score is 0-2 points;
5. The subjects voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up.
Collect HER2 expression in prostate cancer patients
HER2 testing and disease information collection for patients diagnosed with prostate cancer and able to obtain tumor tissue in our hospital from January 2018 to July 2023
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Collect HER2 expression in prostate cancer patients
HER2 testing and disease information collection for patients diagnosed with prostate cancer and able to obtain tumor tissue in our hospital from January 2018 to July 2023
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2\. Men aged ≥ 18 years old;
3\. The expected survival time is greater than 12 weeks;
4\. The KPS functional status score is greater than 60, and the ECOG status score is 0-2 points;
5\. The subjects voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up.
Exclusion Criteria
2\. According to the researcher's judgment, there are other patients who are not suitable for inclusion.
50 Years
90 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Qilu Hospital of Shandong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Qilu hospital
Jinan, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
bks03
Identifier Type: -
Identifier Source: org_study_id